$CRSP
CRISPR Therapeutics AG

2022 Q4 Form 10-Q Financial Statement

#000095017022020845 Filed on November 01, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $6.000K $94.00K
YoY Change -99.95% -88.59%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $27.99M $65.86M
YoY Change 16.02% 170.45%
% of Gross Profit
Research & Development $103.6M $116.6M
YoY Change -22.99% 10.73%
% of Gross Profit
Depreciation & Amortization $5.846M $5.000M
YoY Change -6.63% -5.66%
% of Gross Profit
Operating Expenses $131.5M $182.5M
YoY Change -17.06% 40.72%
Operating Profit -$182.4M
YoY Change 41.55%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $11.49M $7.264M
YoY Change 422.99% 559.76%
Pretax Income -$120.1M -$175.1M
YoY Change -16.34% 37.09%
Income Tax -$9.476M -$600.0K
% Of Pretax Income
Net Earnings -$110.6M -$174.5M
YoY Change -21.72% 37.27%
Net Earnings / Revenue -1842916.67% -185690.43%
Basic Earnings Per Share -$2.24
Diluted Earnings Per Share -$1.41 -$2.24
COMMON SHARES
Basic Shares Outstanding 78.29M 78.01M
Diluted Shares Outstanding 78.02M

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $371.2M $774.1M
YoY Change -72.06% -48.14%
Cash & Equivalents $211.9M $494.2M
Short-Term Investments $159.3M $279.9M
Other Short-Term Assets $37.71M $36.68M
YoY Change -0.97% -11.45%
Inventory
Prepaid Expenses
Receivables $0.00 $49.00K
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.853B $1.933B
YoY Change -23.35% -23.27%
LONG-TERM ASSETS
Property, Plant & Equipment $163.6M $166.1M
YoY Change 18.94% 56.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $53.13M $77.15M
YoY Change
Other Assets $4.640M $3.682M
YoY Change -12.3% -23.1%
Total Long-Term Assets $390.0M $420.7M
YoY Change 16.65% 38.93%
TOTAL ASSETS
Total Short-Term Assets $1.853B $1.933B
Total Long-Term Assets $390.0M $420.7M
Total Assets $2.243B $2.353B
YoY Change -18.49% -16.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $27.43M $32.11M
YoY Change 85.12% 215.87%
Accrued Expenses $77.68M $103.0M
YoY Change -14.64% 50.73%
Deferred Revenue $0.00
YoY Change -100.0%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $121.1M $150.9M
YoY Change 1.02% 56.82%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.969M $5.314M
YoY Change -18.67% -34.28%
Total Long-Term Liabilities $5.969M $5.314M
YoY Change -18.67% -34.28%
TOTAL LIABILITIES
Total Short-Term Liabilities $121.1M $150.9M
Total Long-Term Liabilities $5.969M $5.314M
Total Liabilities $367.6M $399.4M
YoY Change 4.3% 29.34%
SHAREHOLDERS EQUITY
Retained Earnings -$846.1M -$735.5M
YoY Change 331.87% 1245.45%
Common Stock $2.737B $2.712B
YoY Change 5.26% 5.58%
Preferred Stock
YoY Change
Treasury Stock (at cost) $63.00K $63.00K
YoY Change 0.0% 0.0%
Treasury Stock Shares $180.3K $180.3K
Shareholders Equity $1.875B $1.954B
YoY Change
Total Liabilities & Shareholders Equity $2.243B $2.353B
YoY Change -18.49% -16.6%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$110.6M -$174.5M
YoY Change -21.72% 37.27%
Depreciation, Depletion And Amortization $5.846M $5.000M
YoY Change -6.63% -5.66%
Cash From Operating Activities -$113.3M -$105.2M
YoY Change 31.72% 29.37%
INVESTING ACTIVITIES
Capital Expenditures $6.191M -$6.017M
YoY Change -167.42% -83.76%
Acquisitions
YoY Change
Other Investing Activities -$169.3M $93.48M
YoY Change -36361.46% -117.7%
Cash From Investing Activities -$175.5M $87.46M
YoY Change 1913.91% -115.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.478M 15.11M
YoY Change -60.66% 47.98%
NET CHANGE
Cash From Operating Activities -113.3M -105.2M
Cash From Investing Activities -175.5M 87.46M
Cash From Financing Activities 2.478M 15.11M
Net Change In Cash -286.4M -2.642M
YoY Change 223.76% -99.58%
FREE CASH FLOW
Cash From Operating Activities -$113.3M -$105.2M
Capital Expenditures $6.191M -$6.017M
Free Cash Flow -$119.5M -$99.20M
YoY Change 55.51% 124.03%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
6300
dei Entity Address City Or Town
EntityAddressCityOrTown
Zug
dei Entity Address Country
EntityAddressCountry
CH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei City Area Code
CityAreaCode
41 (0)41
dei Local Phone Number
LocalPhoneNumber
561 32 77
dei Security12b Title
Security12bTitle
Common Shares, nominal value CHF 0.03
dei Trading Symbol
TradingSymbol
CRSP
dei Entity Registrant Name
EntityRegistrantName
CRISPR THERAPEUTICS AG
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
V8
dei Entity Address Address Line1
EntityAddressAddressLine1
Baarerstrasse 14
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001674416
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37923
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
78294139
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
494151000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
923031000
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1401824000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1456098000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
49000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
305000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
36679000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
38079000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
1932703000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
2417513000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
166110000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
137575000
CY2022Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
77147000
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
84000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
125000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
12123000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
16913000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
161507000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
174460000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3682000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5291000
CY2022Q3 us-gaap Assets
Assets
2353356000
CY2021Q4 us-gaap Assets
Assets
2751877000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
32114000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14816000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
102954000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
91003000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1011000
CY2022Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
4272000
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
724000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11260000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12158000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
270000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
171000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
150870000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
119883000
CY2022Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
12323000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
12323000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
230895000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
212872000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5314000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7339000
CY2022Q3 us-gaap Liabilities
Liabilities
399402000
CY2021Q4 us-gaap Liabilities
Liabilities
352417000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150347467
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
145364335
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
78428146
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77170382
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
78247830
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76990066
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
2433000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2391000
CY2022Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
180316
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
180316
CY2022Q3 us-gaap Treasury Stock Value
TreasuryStockValue
63000
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
63000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2709361000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2598114000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-735515000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-195915000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-22262000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5067000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
1953954000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2399460000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2353356000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2751877000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
94000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
824000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1192000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
902064000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
116622000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
83500000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
358090000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
237472000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27001000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23709000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
81295000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
76012000
CY2022Q3 crsp Collaboration Expense
CollaborationExpense
38859000
CY2021Q3 crsp Collaboration Expense
CollaborationExpense
22464000
crsp Collaboration Expense
CollaborationExpense
103427000
crsp Collaboration Expense
CollaborationExpense
69354000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
182482000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
129673000
us-gaap Operating Expenses
OperatingExpenses
542812000
us-gaap Operating Expenses
OperatingExpenses
382838000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-182388000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-128849000
us-gaap Operating Income Loss
OperatingIncomeLoss
-541620000
us-gaap Operating Income Loss
OperatingIncomeLoss
519226000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7264000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1101000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11171000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3806000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7264000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1101000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11171000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3806000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-175124000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-127748000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-530449000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
523032000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-575000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-595000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9151000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4123000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-174549000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-127153000
us-gaap Net Income Loss
NetIncomeLoss
-539600000
us-gaap Net Income Loss
NetIncomeLoss
518909000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-100000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-24000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-195000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-14000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1820000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-117000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-17001000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-673000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-176469000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-127294000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-556796000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
518222000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.24
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.85
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78021520
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76288534
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77547771
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75712437
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.24
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.96
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
6.44
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78021520
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76288534
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77547771
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80554682
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1664234000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
222175000
CY2021Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
3000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9784000
CY2021Q1 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
751000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22092000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-378000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-113163000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
1805498000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10909000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28331000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-168000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
759225000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
2603795000
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
4000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8875000
CY2021Q3 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
1344000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26199000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-141000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-127153000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
2512923000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
2399460000
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
4000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10010000
CY2022Q1 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
740000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25745000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-11826000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-179217000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
2244916000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10346000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24852000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3449000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-185834000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
2090831000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
970000
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12782000
CY2022Q3 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
1296000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24543000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1920000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-174549000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
1953954000
us-gaap Profit Loss
ProfitLoss
-539600000
us-gaap Profit Loss
ProfitLoss
518909000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
18326000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
11692000
us-gaap Share Based Compensation
ShareBasedCompensation
75142000
us-gaap Share Based Compensation
ShareBasedCompensation
76622000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-12251000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-9420000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-256000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7062000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
18775000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
36261000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
14733000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-762000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-779000
crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
10826000
crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
19679000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-2175000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-6483000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-382413000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
625010000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
30997000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
72522000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
923404000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1386785000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
871278000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
432593000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-83123000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1026714000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
970000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
213267000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
35144000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
31379000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
36114000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
244646000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-195000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-14000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-429617000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-157072000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
939944000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1185468000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
510327000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1028396000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4919000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6264000
crsp Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
299000
crsp Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
391000
crsp Leasehold Improvements Paid Directly By Landlord
LeaseholdImprovementsPaidDirectlyByLandlord
19252000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
494151000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1011548000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
12123000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
16848000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
510327000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1028396000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, revenue recognition, equity-based compensation expense and reported amounts of expenses during the period. Significant estimates in these consolidated financial statements have been made in connection with revenue recognition and equity-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Changes in estimates are reflected in reported results in the period in which they become known.</span></p>
CY2022Q3 us-gaap Marketable Securities
MarketableSecurities
279900000
CY2021Q4 us-gaap Marketable Securities
MarketableSecurities
405600000
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
214297000
CY2022Q3 crsp Cash Equivalents Gross Unrealized Gains Before Tax
CashEquivalentsGrossUnrealizedGainsBeforeTax
2000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
82.40
CY2022Q3 crsp Cash Equivalents Gross Unrealized Losses Before Tax
CashEquivalentsGrossUnrealizedLossesBeforeTax
25000
CY2022Q3 crsp Cash Equivalents Fair Value
CashEquivalentsFairValue
214274000
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1501052000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
39000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
22120000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1478971000
CY2022Q3 crsp Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1715349000
CY2022Q3 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax
41000
CY2022Q3 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax
22145000
CY2022Q3 crsp Cash Equivalents And Available For Sale Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue
1693245000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
517383000
CY2021Q4 crsp Cash Equivalents Gross Unrealized Losses Before Tax
CashEquivalentsGrossUnrealizedLossesBeforeTax
1000
CY2021Q4 crsp Cash Equivalents Fair Value
CashEquivalentsFairValue
517382000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1461200000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
16000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5118000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1456098000
CY2021Q4 crsp Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1978583000
CY2021Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax
16000
CY2021Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax
5119000
CY2021Q4 crsp Cash Equivalents And Available For Sale Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue
1973480000
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
814900000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
1311600000
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
506200000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
4600000
CY2022Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
77100000
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
0.0
CY2022Q3 crsp Debt Securities Available For Sale Securities Remaining Maturity Greater Than Three Year
DebtSecuritiesAvailableForSaleSecuritiesRemainingMaturityGreaterThanThreeYear
0
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
194078000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
175382000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
27968000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
37807000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
166110000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
137575000
CY2022Q3 us-gaap Depreciation
Depreciation
5000000.0
us-gaap Depreciation
Depreciation
18300000
CY2021Q3 us-gaap Depreciation
Depreciation
5300000
us-gaap Depreciation
Depreciation
11700000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
18906000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
23661000
CY2022Q3 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
69485000
CY2021Q4 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
47986000
CY2022Q3 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
1239000
CY2021Q4 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
138000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4834000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4720000
CY2022Q3 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
3790000
CY2021Q4 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
6120000
CY2022Q3 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
3966000
CY2021Q4 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
7113000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
734000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1265000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
102954000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
91003000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150347467
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150347467
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
145364335
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24543000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26199000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
75142000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
76622000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7812982
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
58.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1143989
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
59.84
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1053443
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
32.17
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
649697
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7253831
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
59.93
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4637194
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
49.37
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7253831
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
59.93
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
121400000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-174549000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-127153000
us-gaap Net Income Loss
NetIncomeLoss
-539600000
us-gaap Net Income Loss
NetIncomeLoss
518909000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78021520
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76288534
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77547771
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75712437
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78021520
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76288534
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77547771
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80554682
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.24
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.85
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.24
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.96
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
6.44
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8583680
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8911688
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8583680
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1706783
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-600000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9200000
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.003
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.017
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-600000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4100000
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.005
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.008

Files In Submission

Name View Source Status
0000950170-22-020845-index-headers.html Edgar Link pending
0000950170-22-020845-index.html Edgar Link pending
0000950170-22-020845.txt Edgar Link pending
0000950170-22-020845-xbrl.zip Edgar Link pending
crsp-20220930.htm Edgar Link pending
crsp-20220930.xsd Edgar Link pending
crsp-ex31_1.htm Edgar Link pending
crsp-ex31_2.htm Edgar Link pending
crsp-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
crsp-20220930_def.xml Edgar Link unprocessable
crsp-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
crsp-20220930_lab.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
crsp-20220930_cal.xml Edgar Link unprocessable
crsp-20220930_htm.xml Edgar Link completed